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Introduction {#rcr2204-sec-0001}
============

*Clostridium difficile* is a spore forming Gram‐positive organism responsible for antibiotic associated colitis. In cystic fibrosis (CF) patients, the prevalence of asymptomatic gastrointestinal colonization by *C. difficile* (22--46%) is higher than in healthy (3%) and hospitalized (20%) adults. Despite these relatively high carriage rates and frequent exposure to known risk factors, *C. difficile* infection (CDI) appears infrequent in CF.

Case Report {#rcr2204-sec-0002}
===========

This case report comprises three cases of near fatal CDI in pre‐transplantation adults with CF (Table [1](#rcr2204-tbl-0001){ref-type="table-wrap"}). All three patients had recently received intravenous antibiotics for respiratory exacerbations within 7--21 days prior to their presentation. All patients presented with severe abdominal pain, fever, and tachycardia. Of note, none had diarrhoea. Blood test showed leucocytosis and hypoalbuminaemia. All patients were stool positive for *C. difficile* toxin. All three patients had severe pancolitis on abdominal CT (Fig. [1](#rcr2204-fig-0001){ref-type="fig"}). Two patients underwent sigmoidoscopy, which confirmed pseudomembranous colitis (Fig. [2](#rcr2204-fig-0002){ref-type="fig"}). Antibiotic treatment for *C. difficile* was commenced between 24 and 120 hours after symptom onset. The clinical course was complicated by severe abdominal pain and distension, along with respiratory and nutritional failure in all three patients. All three patients required parenteral antipseudomonal antibiotics for the treatment of concurrent respiratory exacerbation precipitated by the severe colitis, and also total parenteral nutrition. No surgical intervention was required by any of these patients, and all of them survived. The length of hospitalization ranged from 28 to 38 days. At 12 months follow‐up, none of these patients experienced recurrent CDI despite having been exposed to further courses of antipseudomonal antibiotics.

###### 

Summary of clinical presentations of three cases of severe pseudomembranous colitis.

                                                                    Case 1                                    Case 2                                                          Case 3
  ----------------------------------------------------------------- ----------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------
  Patient characteristics                                                                                                                                                     
  Age, gender                                                       32, male                                  24, male                                                        23, female
  Genotype                                                          F508del/3659delC                          F508del/1154insTC                                               Homozygous F508del
  FEV~1~ (% predicted)                                              74                                        48                                                              45
  GORD                                                              Yes                                       Yes                                                             Yes
  Recent antibiotics                                                14 days as outpatient:                    17 days as inpatient:                                           21 days as inpatient:
  IV tazocin                                                        IV meropenem                              IV ceftazidime                                                  
  IV tobramycin                                                     IV ceftazidime                            IV imipenem                                                     
  PO ciprofloxacin                                                  IV tobramycin                                                                                             
                                                                    PO ciprofloxacin                                                                                          
  Days from end of the last antibiotic course to CDI presentation   21                                        7                                                               14
  Antacid therapy                                                   Pantoprazole                              Pantoprazole                                                    Ranitidine
  Clinical presentation                                                                                                                                                       
  Diarrhoea                                                         Absent                                    Absent                                                          Absent
  Vomiting                                                          No                                        Yes                                                             Yes
  Abdominal pain                                                    Severe---generalized                      Severe---right iliac fossa                                      Severe---generalized
  Temperature (°C)                                                  38.7                                      38.2                                                            38.6
  HR (/min)                                                         110                                       130                                                             125
  BP (mmHg)                                                         135/75                                    115/70                                                          115/80
  WCC (×10^9^ L)                                                    17.7                                      65.7                                                            16
  CRP (mg/L)                                                        54                                        ---                                                             248
  Lactate (mmol/L)                                                  2.1                                       2.5                                                             ---
  Albumin (g/L)                                                     26                                        24                                                              16
  Cr (µmol/L)                                                       75                                        155                                                             70
  Diagnostic testing                                                                                                                                                          
  *C. difficile* toxin A + B                                        Positive on day 3                         Positive on day 2                                               Positive on day 2
  Abdominal CT                                                      Proximal/transverse colitis               Pancolitis (Fig. [1](#rcr2204-fig-0001){ref-type="fig"})        Pancolitis
  Limited sigmoidoscopy                                             Pseudomembranes                           Pseudomembranes (Fig. [2](#rcr2204-fig-0002){ref-type="fig"})   ---
  Pathology                                                         Pseudomembranous colitis                  Pseudomembranous colitis                                        ---
  Complications                                                     Respiratory failure                       Respiratory failure                                             Respiratory failure
  Severe oedema and ascites                                         Severe oedema and ascites                 Re‐feeding syndrome                                             
                                                                    Acute renal failure                       Chest sepsis and haemoptysis                                    
  Specific CDI treatment                                            PO metronidazole                          IV/PO/PR metronidazole                                          PO metronidazole
  PO vancomycin                                                     PO vancomycin                             PO vancomycin                                                   
  Duration of CDI therapy                                           2 weeks of vancomycin and metronidazole   4 weeks of inpatient metronidazole and vancomycin               6 weeks of vancomycin
                                                                    6 months of outpatient oral vancomycin    3 weeks of metronidazole                                        
  Length of admission (days)                                        38                                        35                                                              28
  FEV~1~ (% predicted) on discharge)                                59                                        45                                                              42
  12‐Month follow‐up                                                No further Ab courses                     No further Ab courses                                           No further recurrence of CDI despite further Ab courses
  Prophylaxis during subsequent Ab therapy                          NA                                        NA                                                              PO vancomycin

Ab, antibiotic; BP, blood pressure; Cr, creatinine; CRP, C‐reactive protein; CT, computed tomography; FEV~1~, forced expiratory volume in the first second; HR, heart rate; GORD, gastro‐oesophageal reflux disease; IV, intravenous; PO, per oral; PR, per rectum; WCC, white cell count.

![CT of the abdomen (Case 2) demonstrated marked, diffuse generalized oedema and thickening of the colon. The colonic wall thickness measures up to 22 mm. The eaccordion sign" is present with mucosal thickening, producing alternating oedematous haustral folds separated by transverse mucosal ridges (arrow).](RCR2-5-0-g001){#rcr2204-fig-0001}

![Endoscopic photograph (Case 2) of the transverse colon showing oedematous mucosa with thick overlying pseudomembrane (arrowhead), without overt necrosis.](RCR2-5-0-g002){#rcr2204-fig-0002}

Discussion {#rcr2204-sec-0003}
==========

A literature search on Medline, EMBASE, and PubMed databases identified several reports of severe CDI in adults with CF including those who had received lung transplant [1](#rcr2204-bib-0001){ref-type="ref"}, [2](#rcr2204-bib-0002){ref-type="ref"}. Many patients with CF, including the three patients highlighted in this case report, did not have diarrhoea at their initial presentation with severe CDI. The atypical presentation has contributed to potential delays in presentation, diagnosis, and treatment of severe CDI in CF. Severe CDI is associated with significant morbidity and mortality in post‐transplantation patients with CF [1](#rcr2204-bib-0001){ref-type="ref"}, [2](#rcr2204-bib-0002){ref-type="ref"}.

The rates of asymptomatic *C. difficile* carriage are high in CF [3](#rcr2204-bib-0003){ref-type="ref"}. Therefore, it is surprising that severe CDI is not more frequently observed [3](#rcr2204-bib-0003){ref-type="ref"}. There are several possible explanations for this observation, including: (1) prolonged gastrointestinal transit time in CF facilitates bacterial overgrowth which may increase the number of intestinal species with inhibitory effects on *C. difficile* [3](#rcr2204-bib-0003){ref-type="ref"}; (2) reduced intestinal pH in CF [3](#rcr2204-bib-0003){ref-type="ref"} may be protective against CDI; (3) immunological response to previous *C. difficile* toxin exposure may reduce the risk of clinical disease; and (4) patients with new *C. difficile* acquisition are more likely to develop CDI than those chronically colonized with *C. difficile*. Therefore, the higher *C. difficile* colonization rate may be protective against CDI. The reduced frequency of diarrhoea in CDI may be due to CFTR dysfunction‐related enterocyte insensitivity to diarrhoea‐causing toxins of *C. difficile*, similar to its response to cholera toxin [3](#rcr2204-bib-0003){ref-type="ref"}. Key practice points in the management of CDI in CF include the below.Abdominal pain can be due to many factors in people with CF [3](#rcr2204-bib-0003){ref-type="ref"} and diarrhoea is not a cardinal feature of CDI in CF. Therefore, a healthy level of suspicion for CDI is required when patients with CF present with abdominal symptoms. Vigilant *C. difficile* toxin testing and early abdominal imaging should be considered if a patient has significant abdominal pain or distension. Abdominal CT scan often reveals large intestine distension, colonic wall thickening, fat stranding, and unexplained ascites (Fig. [1](#rcr2204-fig-0001){ref-type="fig"}).Therapy should be initiated for suspected CDI with oral or intravenous metronidazole for mild to moderate presentations. Oral vancomycin should be initiated for severe cases for 10--14 days [4](#rcr2204-bib-0004){ref-type="ref"}. In severe CDI cases where oral vancomycin is poorly tolerated, current guideline recommends nasogastric and rectal administration of vancomycin in combination with intravenous metronidazole [4](#rcr2204-bib-0004){ref-type="ref"}.For refractory CDI, combination antimicrobials (vancomycin and metronidazole) or alternative antimicrobial agents (e.g. tigecycline) are recommended [4](#rcr2204-bib-0004){ref-type="ref"}. Bowel perforation, toxic megacolon and clinical deterioration despite antibiotic therapy are indications for surgery, most commonly, subtotal colectomy with an end‐ileostomy [4](#rcr2204-bib-0004){ref-type="ref"}.In recurrent CDI, oral vancomycin is recommended as first‐line treatment. Alternative therapies such as oral fidaxomicin, rifampicin, nitazoxanide, or faecal microbiota transplantation are potential options in selected patients with recurrent CDI who are not amenable to first‐line treatment [4](#rcr2204-bib-0004){ref-type="ref"}.Early nutritional support is necessary in severe CDI in patients with CF. If enteral nutrition is not feasible total parenteral nutrition may be required.Regular airway clearance should be maintained throughout the acute illness. Whilst avoidance of intravenous antibiotics is advised, this is not always practical in patients with concurrent exacerbations of their CF airways disease.The role of secondary prophylaxis in a patient who has previously had CDI is unknown. There are no guidelines to support this decision. However, concurrent oral metronidazole or vancomycin appears reasonable during antibiotic treatment in patients with CF who had experienced a recent episode of CDI within the last few months. Moderate evidence exists on the efficacy of probiotics in reducing the risk of primary CDI [5](#rcr2204-bib-0005){ref-type="ref"}; however, its efficacy in preventing recurrent CDI remains unclear.Patient education on symptom recognition of CDI is important in facilitating early presentation and treatment in CF.
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